Intensity Therapeutics, Inc. (INTS) stock
INTSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$3.28+0.19 (+6.15%)
Close on Nov 11, 2026Market cap $10.71MP/E –Yield –
Intensity Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Intensity Therapeutics's total assets was $10.29M at Sep 30, 2026. For fiscal 2025 it was $14.10M, up 194.8% from the year before.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.10M | +194.8% |
| FY2024 | Dec 31, 2024 | $4.78M | -72.3% |
| FY2023 | Dec 31, 2023 | $17.30M | +884.3% |
| FY2022 | Dec 31, 2022 | $1.76M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $10.29M | +7.3% |
| Q2 FY2026 | Jun 30, 2026 | $11.52M | +159.3% |
| Q1 FY2026 | Mar 31, 2026 | $12.29M | +301.0% |
| Q4 FY2025 | Dec 31, 2025 | $14.10M | +194.8% |
| Q3 FY2025 | Sep 30, 2025 | $9.59M | +83.9% |
| Q2 FY2025 | Jun 30, 2025 | $4.44M | -48.8% |
| Q1 FY2025 | Mar 31, 2025 | $3.07M | -75.3% |
| Q4 FY2024 | Dec 31, 2024 | $4.78M | -72.3% |
| Q3 FY2024 | Sep 30, 2024 | $5.21M | -69.0% |
| Q2 FY2024 | Jun 30, 2024 | $8.67M | -52.4% |
| Q1 FY2024 | Mar 31, 2024 | $12.41M | +606.2% |
| Q4 FY2023 | Dec 31, 2023 | $17.30M | – |
| Q3 FY2023 | Sep 30, 2023 | $16.82M | – |
| Q2 FY2023 | Jun 30, 2023 | $18.23M | – |
| Q4 FY2022 | Dec 31, 2022 | $1.76M | – |
See a number that looks wrong?